CN113786477A - 一款治疗不孕不育的复合营养制剂及其制备方法 - Google Patents

一款治疗不孕不育的复合营养制剂及其制备方法 Download PDF

Info

Publication number
CN113786477A
CN113786477A CN202111224227.0A CN202111224227A CN113786477A CN 113786477 A CN113786477 A CN 113786477A CN 202111224227 A CN202111224227 A CN 202111224227A CN 113786477 A CN113786477 A CN 113786477A
Authority
CN
China
Prior art keywords
parts
vitamin
percent
composite
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111224227.0A
Other languages
English (en)
Inventor
石红涛
石金
石瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Renliang Pharmaceutical Group Co ltd
Original Assignee
Shanghai Renliang Pharmaceutical Group Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Renliang Pharmaceutical Group Co ltd filed Critical Shanghai Renliang Pharmaceutical Group Co ltd
Priority to CN202111224227.0A priority Critical patent/CN113786477A/zh
Publication of CN113786477A publication Critical patent/CN113786477A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及中药制剂技术领域，公开了一款治疗不孕不育的复合营养制剂，按重量份组成如下：15～20份小麦胚芽素粉、8～12份蛋黄粉、15～20份大豆粉、28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐。本发明通过小麦胚芽素粉、蛋黄粉、大豆粉、结晶果糖、复合蛋白质、复合脂肪、复合维生素、复合矿物质、乳矿物盐和钠盐制备成复合营养制剂，可以显著改善不孕不育患者的痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物、性交痛、神经压力、流产后并发症、盆腔感染性疾病，进而可以显著不孕不育患者的受孕率。

Description

一款治疗不孕不育的复合营养制剂及其制备方法
技术领域
本发明涉及中药制剂技术领域，具体是一款治疗不孕不育的复合营养制剂及其制备方法。
背景技术
临床上，不孕不育症十分常见，并有继续上升的趋势，给广大女性健康以及家庭和谐造成了严重影响，主要离不开输卵管堵塞、子宫内膜异位、卵巢早衰或排卵异常、阴道感染、宫颈缺失或畸形或发育不全、骨盆腔粘连、反复人流等内在因素，除了内在因素，不良的生活习惯，比如抽烟酗酒、熬夜晚睡、暴饮暴食、减肥节食、久坐不动、内分泌失调、滥服药物；另外，压力过大、环境污染等外在因素也会导致不孕不育，因此通过药物对不孕不育症进行治疗势在必行。
中国专利公开了一种治疗女性不孕不育的中药制剂及其制备方法(授权公告号CN101095804A)，该专利技术由当归、丹参、重楼、苦参、土茯苓等中药以及辅料制成片剂、胶囊剂、丸剂、口服剂、散剂、膏剂、丹剂等口服剂型或注射剂，该制剂用于女性不孕不育等疾病的治疗，且制剂作用独特，制备简单，服用方便，疗效显著的特点，但是其对治疗不孕症的效果并不明显，不能显著的降低各种影响不孕不育因素的症状。
发明内容
本发明的目的在于提供一款治疗不孕不育的复合营养制剂及其制备方法，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一款治疗不孕不育的复合营养制剂，包括小麦胚芽素粉、蛋黄粉、大豆粉、结晶果糖、复合蛋白质、复合脂肪、复合维生素、复合矿物质、乳矿物盐和钠盐，其特征在于，按重量份组成如下：15～20份小麦胚芽素粉、8～12份蛋黄粉、15～20份大豆粉、28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐，其中，所述复合蛋白质按重量比组成包括：25％～32％浓缩乳清蛋白、18％～24％清蛋白多肽、32％～40％乳清肽和4％～6％牛磺酸。
作为本发明进一步的方案：所述复合脂肪按重量比组成包括：55％～60％磷脂、35％～38％亚麻籽油微囊粉、2％～4％表没食子儿茶素没食子酸酯。
作为本发明再进一步的方案：所述复合维生素按重量比组成包括：0.28％～0.35％维生素A、0.0031％～0.0034％维生素D、6.60％～6.70％维生素E、0.72％～0.82％维生素B1、0.72％～0.82％维生素B2、0.98％～1.08％维生素B6、0.0012％～0.0014％维生素B12、78.20％～79.20％维生素C、0.11％～0.13％叶酸、6.55％～6.65％烟酸、0.27％～0.31％生物素和4.15％～4.45％泛酸。
作为本发明再进一步的方案：所述维生素A选用醋酸维生素A，所述维生素D选用胆钙化醇，所述维生素E选用dl-α-醋酸生育酚，所述维生素B1选用盐酸硫胺素，所述维生素B2选用核黄素，所述维生素B6选用盐酸吡哆醇，所述维生素B12选用氰钴氨，所述维生素C选用L-抗坏血酸，所述烟酸选用烟酰胺，所述生物素选用D-生物素，所述泛酸选用D-泛酸钙。
作为本发明再进一步的方案：所述复合矿物质按重量比组成包括：91.5％～93.5％氧化镁、3.76％～4.13％焦磷酸铁、3.12％～3.22％葡萄糖酸锌和0.015％～0.019％亚硒酸钠。
一款治疗不孕不育的复合营养制剂的制备方法，包括以下步骤：
S1、将小麦胚芽素粉、蛋黄粉和大豆粉烘干后，分别取15～20份小麦胚芽素粉、8～12份蛋黄粉和15～20份大豆粉混合机中均匀混合；
S2、将结晶果糖研磨成粉，将复合蛋白质冻干后研磨成粉，再将复合维生素、复合矿物质、乳矿物盐和钠盐分别研磨成粉，分别取28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐，加入到S1步骤中的混合机中，再次均匀混合，制得复合营养制剂；
S3、将S2步骤中制得的复合营养制剂烘干后，称量、灌装成小袋，每袋10g。
与现有技术相比，本发明的有益效果：
本发明通过小麦胚芽素粉、蛋黄粉、大豆粉、结晶果糖、复合蛋白质、复合脂肪、复合维生素、复合矿物质、乳矿物盐和钠盐制备成复合营养制剂，可以显著改善不孕不育患者的痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物、性交痛、神经压力、流产后并发症、盆腔感染性疾病，进而可以显著不孕不育患者的受孕率。
具体实施方式
本发明实施例中，一款治疗不孕不育的复合营养制剂，包括小麦胚芽素粉、蛋黄粉、大豆粉、结晶果糖、复合蛋白质、复合脂肪、复合维生素、复合矿物质、乳矿物盐和钠盐，按重量份组成如下：15～20份小麦胚芽素粉、8～12份蛋黄粉、15～20份大豆粉、28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐，其中，复合蛋白质按重量比组成包括：25％～32％浓缩乳清蛋白、18％～24％清蛋白多肽、32％～40％乳清肽和4％～6％牛磺酸。
优选的，复合脂肪按重量比组成包括：55％～60％磷脂、35％～38％亚麻籽油微囊粉、2％～4％表没食子儿茶素没食子酸酯。
优选的，复合维生素按重量比组成包括：0.28％～0.35％维生素A、0.0031％～0.0034％维生素D、6.60％～6.70％维生素E、0.72％～0.82％维生素B1、0.72％～0.82％维生素B2、0.98％～1.08％维生素B6、0.0012％～0.0014％维生素B12、78.20％～79.20％维生素C、0.11％～0.13％叶酸、6.55％～6.65％烟酸、0.27％～0.31％生物素和4.15％～4.45％泛酸。
优选的，维生素A选用醋酸维生素A，维生素D选用胆钙化醇，维生素E选用dl-α-醋酸生育酚，维生素B1选用盐酸硫胺素，维生素B2选用核黄素，维生素B6选用盐酸吡哆醇，维生素B12选用氰钴氨，维生素C选用L-抗坏血酸，烟酸选用烟酰胺，生物素选用D-生物素，泛酸选用D-泛酸钙。
优选的，复合矿物质按重量比组成包括：91.5％～93.5％氧化镁、3.76％～4.13％焦磷酸铁、3.12％～3.22％葡萄糖酸锌和0.015％～0.019％亚硒酸钠。
一款治疗不孕不育的复合营养制剂的制备方法，包括以下步骤：
S1、将小麦胚芽素粉、蛋黄粉和大豆粉烘干后，分别取15～20份小麦胚芽素粉、8～12份蛋黄粉和15～20份大豆粉混合机中均匀混合；
S2、将结晶果糖研磨成粉，将复合蛋白质冻干后研磨成粉，再将复合维生素、复合矿物质、乳矿物盐和钠盐分别研磨成粉，分别取28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐，加入到S1步骤中的混合机中，再次均匀混合，制得复合营养制剂；
S3、将S2步骤中制得的复合营养制剂烘干后，称量、灌装成小袋，每袋10g。
为了更好地说明本发明的技术效果，通过下述试验进行阐述：
采用单纯随机抽样方法抽取半年内在某医院就诊的不孕症患者120例，该120例患者婚后曾有过妊娠(包括足月妊娠、早产、流产、异位妊娠、葡萄胎)而后同居有正常性生活、未避孕1年以上，并排除女性有先天性或后天性解剖上或功能上的缺陷，无法校正而不能受孕的绝对不孕者，经检查，其男性伴侣均无性功能障碍、不孕不育等症状。
将该120例患者随机分为实施例组、对比例一组和对比例二组，共三组，每组40人，经分析：实施例组中，年龄段26～41岁，平均年龄(33.32±1.85)岁，有正常性生活、未避孕平均时间(3.12±0.46)年；对比例一组中，年龄段28～40岁，平均年龄(34.02±2.31)岁，有正常性生活、未避孕平均时间(3.59±0.57)年；对比例二组中，年龄段27～39岁，平均年龄(33.76±2.19)岁，有正常性生活、未避孕平均时间(3.42±0.54)年，三组患者在年龄、性生活时间上经统计学处理，差异无统计学意义，具有可比性。
其中实施例组：采用本发明制成的复合营养制剂+治疗炎症的药物(如各种抗菌素)+促排卵药物(如克罗米酚、卵泡刺激素等)进行治疗，对比例一组采用中国专利公开的一种治疗女性不孕不育的中药制剂及其制备方法(公开日：2011-01-19，公开号：CN101095804B)+治疗炎症的药物(如各种抗菌素)+促排卵药物(如克罗米酚、卵泡刺激素等)进行治疗，对比例二组为对照组，直接采用治疗炎症的药物(如各种抗菌素)+促排卵药物(如克罗米酚、卵泡刺激素等)进行治疗。
食用方法及用量：每日一次，每次一袋，加入150～200ml温开水搅拌溶解后即可饮用；冲调后，如杯底部有黄白色沉淀物系焦磷酸铁等营养剂，属正常现象，不影响食用，以两个星期为一个疗程，治疗六个疗程之后，统计疗效，观察记录每组患者的情况；
一、观察每组患者在治疗前痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物等各种影响不孕不育因素的情况，经过治疗六个疗程之后，再次观察痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物的情况，治疗期间禁止性生活。
对痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物进行变量赋值，其中,无＝0，轻度＝1，中度＝2，较重度＝3，重度＝4，分别计算实施例组、对比例一组和对比例二组中痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病个阴道分必物平均值，记录在下表1中。
表1实施例组、对比例一组和对比例二组影响因素的比较
Figure BDA0003310872680000051
从表1可以分析得出：实施例组、对比例一组、对比例二组中痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物、性交痛、神经压力、流产后并发症、盆腔感染性疾病各因素的数值均较接近，具有可比性，经过治疗后，实施例组对比例一组、对比例二组中各因素的数值均出现不同程度的下降，但实施例组中各因素的下降值显著大于对比例一组、对比例二组中各因素的下降值，从而可以得出：本发明制备的复合营养制剂可以显著改善不孕不育患者的痛经、性交痛、神经压力、流产后并发症、盆腔感染性疾病、阴道分必物、性交痛、神经压力、流产后并发症、盆腔感染性疾病，并促进不孕不育患者受孕。
二、治疗六个疗程之后，停止用药，并进行正常的性生活，6个月后，观察每组中怀孕人数，计算受孕率，并记录下表2中。
表2实施例组、对比例一组和对比例二组受孕人数的比较
Figure BDA0003310872680000061
从表2可以分析得出：治疗六个疗程后，并进行性生活6个月后，实施例组中共有31人成功受孕，受孕率高达77.5％，对比例一组共有19人成功受孕，受孕率为47.5％，对比例二组只有13人成功受孕，受孕率为32.5％，实施例组中的受孕率显著高于对比例一组和对比例二组中的受孕率，从而可以得出：本发明制备的复合营养制剂可以显著不孕不育患者的受孕率。
以上所述的，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。

Claims (6)

1.一款治疗不孕不育的复合营养制剂，包括小麦胚芽素粉、蛋黄粉、大豆粉、结晶果糖、复合蛋白质、复合脂肪、复合维生素、复合矿物质、乳矿物盐和钠盐，其特征在于，按重量份组成如下：15～20份小麦胚芽素粉、8～12份蛋黄粉、15～20份大豆粉、28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐，其中，所述复合蛋白质按重量比组成包括：25％～32％浓缩乳清蛋白、18％～24％清蛋白多肽、32％～40％乳清肽和4％～6％牛磺酸。
2.根据权利要求1所述的一款治疗不孕不育的复合营养制剂，其特征在于，所述复合脂肪按重量比组成包括：55％～60％磷脂、35％～38％亚麻籽油微囊粉、2％～4％表没食子儿茶素没食子酸酯。
3.根据权利要求1所述的一款治疗不孕不育的复合营养制剂，其特征在于，所述复合维生素按重量比组成包括：0.28％～0.35％维生素A、0.0031％～0.0034％维生素D、6.60％～6.70％维生素E、0.72％～0.82％维生素B1、0.72％～0.82％维生素B2、0.98％～1.08％维生素B6、0.0012％～0.0014％维生素B12、78.20％～79.20％维生素C、0.11％～0.13％叶酸、6.55％～6.65％烟酸、0.27％～0.31％生物素和4.15％～4.45％泛酸。
4.根据权利要求3所述的一款治疗不孕不育的复合营养制剂，其特征在于，所述维生素A选用醋酸维生素A，所述维生素D选用胆钙化醇，所述维生素E选用dl-α-醋酸生育酚，所述维生素B1选用盐酸硫胺素，所述维生素B2选用核黄素，所述维生素B6选用盐酸吡哆醇，所述维生素B12选用氰钴氨，所述维生素C选用L-抗坏血酸，所述烟酸选用烟酰胺，所述生物素选用D-生物素，所述泛酸选用D-泛酸钙。
5.根据权利要求1所述的一款治疗不孕不育的复合营养制剂，其特征在于，所述复合矿物质按重量比组成包括：91.5％～93.5％氧化镁、3.76％～4.13％焦磷酸铁、3.12％～3.22％葡萄糖酸锌和0.015％～0.019％亚硒酸钠。
6.一款实现权利要求1所述的治疗不孕不育的复合营养制剂的制备方法，其特征在于，包括以下步骤：
S1、将小麦胚芽素粉、蛋黄粉和大豆粉烘干后，分别取15～20份小麦胚芽素粉、8～12份蛋黄粉和15～20份大豆粉混合机中均匀混合；
S2、将结晶果糖研磨成粉，将复合蛋白质冻干后研磨成粉，再将复合维生素、复合矿物质、乳矿物盐和钠盐分别研磨成粉，分别取28～32份结晶果糖、10～12份复合蛋白质、12～15份复合脂肪、2.5～3份复合维生素、3～3.5份复合矿物质、0.5～0.8份乳矿物盐和0.15～0.2份钠盐，加入到S1步骤中的混合机中，再次均匀混合，制得复合营养制剂；
S3、将S2步骤中制得的复合营养制剂烘干后，称量、灌装成小袋，每袋10g。
CN202111224227.0A 2021-10-19 2021-10-19 一款治疗不孕不育的复合营养制剂及其制备方法 Pending CN113786477A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111224227.0A CN113786477A (zh) 2021-10-19 2021-10-19 一款治疗不孕不育的复合营养制剂及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111224227.0A CN113786477A (zh) 2021-10-19 2021-10-19 一款治疗不孕不育的复合营养制剂及其制备方法

Publications (1)

Publication Number Publication Date
CN113786477A true CN113786477A (zh) 2021-12-14

Family

ID=79185057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111224227.0A Pending CN113786477A (zh) 2021-10-19 2021-10-19 一款治疗不孕不育的复合营养制剂及其制备方法

Country Status (1)

Country Link
CN (1) CN113786477A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106942748A (zh) * 2017-03-29 2017-07-14 上海奥医生物医药科技有限公司 一种女性不孕专用型临床营养配方及其制备方法
CN107072276A (zh) * 2014-09-01 2017-08-18 马修·乔利·瓦达科姆里 一种优化的营养食品
CN108095075A (zh) * 2017-12-13 2018-06-01 上海奥医生物医药科技有限公司 流产女性专用型临床营养配方及其制备方法
CN109288067A (zh) * 2018-10-18 2019-02-01 德瑞美医药生物技术盐城有限公司 一种助孕保胎的营养制剂
CN113230276A (zh) * 2021-04-23 2021-08-10 奥启(深圳)创投科技有限公司 一种用于治疗卵巢早衰的干细胞制剂及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072276A (zh) * 2014-09-01 2017-08-18 马修·乔利·瓦达科姆里 一种优化的营养食品
CN106942748A (zh) * 2017-03-29 2017-07-14 上海奥医生物医药科技有限公司 一种女性不孕专用型临床营养配方及其制备方法
CN108095075A (zh) * 2017-12-13 2018-06-01 上海奥医生物医药科技有限公司 流产女性专用型临床营养配方及其制备方法
CN109288067A (zh) * 2018-10-18 2019-02-01 德瑞美医药生物技术盐城有限公司 一种助孕保胎的营养制剂
CN113230276A (zh) * 2021-04-23 2021-08-10 奥启(深圳)创投科技有限公司 一种用于治疗卵巢早衰的干细胞制剂及其制备方法和应用

Similar Documents

Publication Publication Date Title
US6569857B1 (en) Dietary supplement
US6576253B2 (en) Food bars containing nutritional supplements
US6368640B1 (en) Method and composition for improving sexual fitness
US20020102330A1 (en) Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents
EP1176948A1 (en) Anti-nausea compositions and methods
WO1996013179A2 (en) Nutrient supplement compositions providing physiologic feedback
US20040005311A1 (en) Dietary supplement compositions
US6265391B1 (en) Method for preventing peripheral nerve damage
WO2002007768A1 (en) Dietary supplement compositions
CN111771988A (zh) 适用于糖尿病人食用的营养食品及其制备方法
EP1198994B1 (en) Health food products
US20150150904A1 (en) Dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like and method of treatment
US9439913B1 (en) Fat-soluble vitamin formulations
CN113786477A (zh) 一款治疗不孕不育的复合营养制剂及其制备方法
CN108669535A (zh) 一种具有缓解产妇精神紧张的分娩速补能量包及其制备方法
CN112690457A (zh) 一种用于超重和肥胖人群的营养素组合物配方
WO2014016627A1 (en) Vitamin and mineral preparations for gravidae for use in trimesters of pregnancy
AU2021260664B2 (en) Sleep-improving pharmaceutical composition containing rare ginsenosides Rg6 and F4
CN105998140B (zh) 红景天含片
US7371415B1 (en) Method and composition for improving sexual fitness
CA2446254C (en) New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits
CN112244289A (zh) 一种促进围手术期病人康复的营养配方粉的制备方法
CN106620485B (zh) 神曲消食口服组合物的制备方法
US20050266096A1 (en) New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits
AU2015101086B4 (en) A dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like and method of treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination